Q3 2022 Results

Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Our pipeline projects at a glance Innovative medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular Others Ophthalmology Respiratory & Allergy Global Health Biosimilars¹ 1. Selected disclosed, internal projects. 36 Investor Relations | Q3 2022 Results References Abbreviations Phase 1/2 Phase 3 Registration Total 97 44 6 147 23 17 3 43 19 6 0 25 22 9 2 33 6 5 0 11 8 19 52 1 14 0 21 5 1 0 6 4 0 0 4 10 1 0 11 0 2 0 2 Total 97 46 6 149 1 NOVARTIS | Reimagining Medicine

View entire presentation